Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ILNS changed from treatment only to disease prevention with focus in OX1
Could implement it was sold based on preclinical results from Dr. Hyman and Dr. Rohn
Jesselson and Chain hold ILNS majority.
No wonder if we will see a reverse merger with Cerespir, Jesselson and Chain again.
http://www.cerespir.com/in-the-news/
http://www.cerespir.com/board-of-directors/
https://www.streetinsider.com/dr/news.php?id=11284705
I would have the tauc3 results from Dr. Rohn to Finish the preclinical program before selling ILNS. Expect them in the next weeks. Dr. Hyman need 2 years for tauc3 study. Dr. Rohn was initiated in otc. 2015
Have seen this momentum several times, increase in price - last dip - running through the roof
The chart took a deep breath, prepared for a run
Expect Dr. Rohn results soon, initiated otc. 2015
Yes, lets Rock, ILNS is hot!
It supports the ILNS TauC3 antibody studies by Dr. Hyman, Dr. Rohn....
NEW INSIGHT INTO ALZHEIMER'S DISEASE
https://www.omicsonline.org/open-access/new-insight-into-alzheimers-disease-via-caspase-3cleaved-taupathogenic-role-in-tau-oligomer-formation-and-memory-deficits-2161-0460-1000344.php?aid=92671
As I said and the next will be ILNS
The same with ILNS, MAZA 10%, Honig 10%, Jesselson 20%.....
Shorts will lose, MAZA distribute the cards
$ILNS - Intellect Neurosciences- last breath before the run
Buy or....
It is smart to accumuluate before a move!
Bid and Ask going up
MAZA is CEO of IMNP and ILNS - $$$$
ILNS SHP622 White paper - screen it for diabetes or diabetic
http://content.equisolve.net/_31f231c94e07c92a89e1887618f82972/intellectns/db/30/168/pdf/FA+Final+Report+June+2016.pdf
Yes and the agreement for a FA treatment with shire was terminated by Maza in april. indole-3-propionic acid alias OX1 alias SHP622 was tested in a 1a, 1b and a phase 1 clinical trial and it was safe and well tolerated. It may be a treatment for other diseases like diabetes as reported. I guess there was a good reason for the termination in april and if you look at IMNP (CEO Maza) and their contacts and recently initiated clincal trials in scandinavia - read through the lines....
TauC3 is well known and HOT but don't forget the other ILNS options
ALL IMO
About indole3propionic acid alias shp622 and Diabetes....
https://www.sciencedaily.com/releases/2017/04/170411090159.htm
A hot Summer with ILNS IMNP or MGTI
Damn man I want those shares...arrrh
Is ILNS ready for the big move?
MAZA is CEO of IMNP, its trending up
Eg for a preclinical Tau-antibody license deal ($400MM):
http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=584675
Major experts around the globe confirmed tauc3 in last several years....TAUC3 is so HOT
Yes but big Player want to go with tauc3
I have read a lot about TauC3 antibody - it could be a game changer in neurodegenrativ disease. Expect something from Troy Rohn as well..... IMO
"Progressive Supranuclear Palsy Pipeline key players are AB Science SA, AbbVie Inc, AlzProtect SAS, Asceneuron SA, Bristol-Myers Squibb Company, Cortice Biosciences Inc, Intellect Neurosciences Inc, K-Stemcell Co Ltd, Merck & Co Inc, Prana Biotechnology Ltd, TauRx Therapeutics Ltd."
https://www.whatech.com/market-research/industrial/321836-learn-details-of-the-h1-analysis-on-progressive-supranuclear-pals-review-report
https://www.barchart.com/stocks/quotes/ILNS/opinion
This work was supported by a sponsored research agreement from Intellect Neurosciences INC. Intellect Neurosciences also provided the anti-TauC3 antibody.
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0177914
IMO its a reverse merger or a buy out, all IMO